High dose chemotherapy with autologous stem cell rescue in children and young adults with high-risk Ewing sarcoma: A single institute experience in Taiwan.

Chih-Ying Lee, Hsiu-Ju Yen, Ming-Hsin Hou, Giun-Yi Hung, Cheng-Yin Ho, Ting-Yen Yu, Po-Kuei Wu, Chao-Ming Chen, Chueh-Chuan Yen, Cheng-Ying Shiau, Paul Chih-Hsueh Chen, Hung-Ta Hondar Wu, Ching-Lan Wu, Wei-Ming Chen
{"title":"High dose chemotherapy with autologous stem cell rescue in children and young adults with high-risk Ewing sarcoma: A single institute experience in Taiwan.","authors":"Chih-Ying Lee, Hsiu-Ju Yen, Ming-Hsin Hou, Giun-Yi Hung, Cheng-Yin Ho, Ting-Yen Yu, Po-Kuei Wu, Chao-Ming Chen, Chueh-Chuan Yen, Cheng-Ying Shiau, Paul Chih-Hsueh Chen, Hung-Ta Hondar Wu, Ching-Lan Wu, Wei-Ming Chen","doi":"10.1097/JCMA.0000000000001179","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>A combination treatment of surgery, chemotherapy, and radiotherapy can improve the survivals of pediatric patients with Ewing sarcoma (ES). However, prognosis remains poor for patients with metastatic disease at diagnosis or recurrence. Other high-risk (HR) features include large tumor burden, tumors of the axial skeleton and poor histologic response. Several studies have documented high dose chemotherapy with autologous stem cell rescue (HDC-ASCR) to be effective in such patients. In this retrospective study, we present the results of HDC-ASCR for high-risk Ewing sarcoma in children and young adults in a single institute.</p><p><strong>Methods: </strong>From March 2004 to March 2021, patients with ES, Ewing-like sarcoma, or round cell sarcoma received HDC-ASCR as part of treatment were included. The patients' characteristics, disease status, stem cell dose, engraftment status, post-transplant complications, and outcomes were analyzed.</p><p><strong>Results: </strong>Twenty patients receiving HDC-ASCR at complete response (n = 6), partial response (n = 13), and stable disease (n = 1) were enrolled. The male to female ratio was 11:9. Median age at diagnosis and transplant was 15.6 years old (range: 3.3-28.9) and 16.2 (range: 4.2-29.9), respectively. The conditioning regimens included ifosfamide-based in two and melphalan-based in 19. All patients achieved successful engraftment without tansplant-related mortality. The 5-year progression-free and overall survival (OS) rate were 35% and 54.5%, respectively. The causes of death (n = 8) were all contributed to disease progression. Patients in the complete response group or with localized HRES exhibited a higher 5-year OS (p = 0.047 and 0.05, respectively). Compared to the historical cohort without HDC-ASCR as part of primary treatment, the current cohort had a significantly better 5-year OS (p = 0.018).</p><p><strong>Conclusion: </strong>HDC-ASCR seems promising as an alternative treatment for HRES in improving OS in this retrospective study with limited case number.</p>","PeriodicalId":94115,"journal":{"name":"Journal of the Chinese Medical Association : JCMA","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Chinese Medical Association : JCMA","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/JCMA.0000000000001179","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: A combination treatment of surgery, chemotherapy, and radiotherapy can improve the survivals of pediatric patients with Ewing sarcoma (ES). However, prognosis remains poor for patients with metastatic disease at diagnosis or recurrence. Other high-risk (HR) features include large tumor burden, tumors of the axial skeleton and poor histologic response. Several studies have documented high dose chemotherapy with autologous stem cell rescue (HDC-ASCR) to be effective in such patients. In this retrospective study, we present the results of HDC-ASCR for high-risk Ewing sarcoma in children and young adults in a single institute.

Methods: From March 2004 to March 2021, patients with ES, Ewing-like sarcoma, or round cell sarcoma received HDC-ASCR as part of treatment were included. The patients' characteristics, disease status, stem cell dose, engraftment status, post-transplant complications, and outcomes were analyzed.

Results: Twenty patients receiving HDC-ASCR at complete response (n = 6), partial response (n = 13), and stable disease (n = 1) were enrolled. The male to female ratio was 11:9. Median age at diagnosis and transplant was 15.6 years old (range: 3.3-28.9) and 16.2 (range: 4.2-29.9), respectively. The conditioning regimens included ifosfamide-based in two and melphalan-based in 19. All patients achieved successful engraftment without tansplant-related mortality. The 5-year progression-free and overall survival (OS) rate were 35% and 54.5%, respectively. The causes of death (n = 8) were all contributed to disease progression. Patients in the complete response group or with localized HRES exhibited a higher 5-year OS (p = 0.047 and 0.05, respectively). Compared to the historical cohort without HDC-ASCR as part of primary treatment, the current cohort had a significantly better 5-year OS (p = 0.018).

Conclusion: HDC-ASCR seems promising as an alternative treatment for HRES in improving OS in this retrospective study with limited case number.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
高风险尤文肉瘤儿童和青少年患者的大剂量化疗与自体干细胞救治:台湾一家研究所的经验。
背景:手术、化疗和放疗的综合治疗可提高儿童尤文肉瘤(ES)患者的存活率。然而,确诊时有转移性疾病或复发的患者预后仍然很差。其他高危(HR)特征包括肿瘤负荷大、肿瘤位于轴状骨骼和组织学反应差。多项研究表明,大剂量化疗联合自体干细胞救治(HDC-ASCR)对此类患者有效。在这项回顾性研究中,我们介绍了一家研究所采用HDC-ASCR治疗高危儿童和年轻成人尤文肉瘤的结果:方法:纳入 2004 年 3 月至 2021 年 3 月期间接受 HDC-ASCR 治疗的 ES、尤文样肉瘤或圆形细胞肉瘤患者。分析了患者的特征、疾病状态、干细胞剂量、移植状态、移植后并发症和预后:20名患者在完全反应(6人)、部分反应(13人)和病情稳定(1人)时接受了HDC-ASCR治疗。男女比例为 11:9。诊断和移植时的中位年龄分别为 15.6 岁(范围:3.3-28.9)和 16.2 岁(范围:4.2-29.9)。2名患者采用了伊福酰胺治疗方案,19名患者采用了美法仑治疗方案。所有患者都成功实现了移植,且无坦杉相关死亡率。5年无进展生存率和总生存率(OS)分别为35%和54.5%。死亡原因(8 例)均与疾病进展有关。完全应答组或局部HRES患者的5年生存率较高(P = 0.047和0.05)。与未将HDC-ASCR作为主要治疗手段的历史队列相比,当前队列的5年OS明显更好(p = 0.018):结论:在这项病例数有限的回顾性研究中,HDC-ASCR似乎有望作为HRES的替代治疗方法,改善患者的OS。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Onyx as an adjunctive embolic material for transvenous embolization of cavernous sinus dural arteriovenous fistula after coiling. Postoperative rhinosinusitis and microbiological outcomes following endoscopic endonasal approaches: A retrospective analysis of 300 patients. Real-world outcomes of everolimus-based treatment in a Taiwanese cohort with metastatic HR+/HER2- breast cancer. A prediction model of echocardiographic variables to screen for potentially correctable shunts in adult ASD-PAH patients. Risk factors for screw loosening in patients with lumbar degenerative spondylolisthesis treated with Dynesys dynamic stabilization.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1